| Heading: |
Antimicrobials: Small Businesses |
| Question ID: |
1812987 |
| UIN: |
60029 |
| House: |
Commons |
| Date tabled: |
2025-06-16 |
| Asking Member ID: |
4084 |
| Asking Member display name: |
Esther McVey
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Esther McVey
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of new antimicrobial therapeutics developed by SMEs. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The United Kingdom’s 2024 to 2029 national action plan (NAP) to confront antimicrobial resistance (AMR) includes a commitment to work across sectors to develop new antimicrobials. The NAP also acknowledges the potential of alternative therapies, such as b... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |